Showing 1141-1150 of 1616 results for "".
- Allegro Announces Positive Results of Vehicle-Controlled Ex-US Phase 2 Trial of ALG-1007 for the Treatment of Dry Eye Diseasehttps://modernod.com/news/allegro-announces-positive-results-of-vehicle-controlled-ex-us-phase-2-trial-of-alg-1007-for-the-treatment-of-dry-eye-disease/2479410/Allegro Ophthalmics announced that all primary and secondary endpoints of an ex-US vehicle-controlled study of ALG-1007 topical eye drop in patients with dry eye disease (DED) were met. The results were presented by Eric D. Donnenfeld, MD, at the 2021 American Society of Cataract and Refractive S
- Allegro Announces Positive Results of Ex-US Proof-of-Concept Trial With ALG-1007 for Dry Eye Diseasehttps://modernod.com/news/allegro-ophthalmics-announces-positive-results-of-ex-us-proof-of-concept-trial-with-integrin-inhibitor-alg-1007-for-dry-eye-disease/2476583/Allegro Ophthalmics announced positive results of an ex-US proof-of-concept clinical trial of the new investigational ALG-1007 topical drop drug candidate in patients with dry eye disease (DED). The results were presented by Eric D. Donnenfeld, MD, last week at the 2019 American Society of Catara
- AcuFocus Announces Extended Diopter Range for the IC-8 Small Aperture IOLhttps://modernod.com/news/acufocus-announces-extended-diopter-range-for-the-ic-8-small-aperture-iol/2478087/AcuFocus announced that the IC-8 small aperture IOL power range now extends from +10.0 D to +30.0 D (0.50 D steps), offering eye care physicians the opportunity to provide more patients an uninterrupted extended range
- Staar Surgical Celebrates 30th Anniversary of Implantable Collamer Lens (ICL)https://modernod.com/news/staar-surgical-celebrates-30th-anniversary-of-implantable-collamer-lens-icl/2481892/Staar Surgical is celebrating the 30th anniversary of its proprietary Implantable Collamer Lens (ICL). The first ICLs were implanted by a group of surgeons in October 1993, including Roberto Zaldivar, MD, Founder of the Zaldivar Institute. The early ICLs have evolved into the curre
- Children’s Hospital Los Angeles Receives $1.6M Grant to Study Retinoblastomahttps://modernod.com/news/childrens-hospital-los-angeles-receives-1-6m-grant-to-study-retinoblastoma/2476397/Retinoblastoma is a tumor of the retina that generally affects children under 5 years of age and accounts for approximately 4% of childhood cancers. If not diagnosed early, retinoblastoma may result in loss of one or both eyes and can be fatal. David Cobrinik, MD, PhD, of The Saban Researc
- Centricity Vision Announces New Technologies Under Development, Zeptolink and 5.5 mm Capsulotomy; Names Leonard Borrmann to Lead R&Dhttps://modernod.com/news/centricity-vision-announces-new-technologies-under-development-zeptolink-and-55-mm-capsulotomy-names-leonard-borrmann-to-lead-rd/2480783/Centricity Vision announced two product innovations under development, the Zeptolink platform and Zepto 5.5 mm capsulotomy technology. The company has also appointed Leonard Borrmann, PharmD, to lead research and development. "The Zepto technology is elevating the precisi
- Hoya Launches VisuPro Advanced Focus Spectacle Lenses for Patients Experiencing Early Symptoms of Presbyopiahttps://modernod.com/news/hoya-launches-visupro-advanced-focus-spectacle-lenses-for-patients-experiencing-first-symptoms-of-presbyopia/2482724/Hoya has launched its VisuPro All Day and VisuPro Flex advanced focus spectacle lenses, which are designed to help people in their late 30s to mid-40s that are beginning to experience presbyopia. As people enter this age group, they may begi
- Novel Imaging Technology Reveals Role of Immune Cells in Early Diabetic Cataract Developmenthttps://modernod.com/news/novel-imaging-technology-reveals-role-of-immune-cells-in-early-diabetic-cataract-development-1/2481623/Novel findings from researchers at the Brigham and Women's Hospital and Harvard Medical School, in collaboration with the Health Campus Göttingen in Germany, contradict previous notions about sugar's role in the onset of diabetic cataracts, according to a University Medical Center G&
- Aura Biosciences Announces Positive Interim Phase 2 Data of Belzupacap Sarotalocan for Treatment of Early-Stage Choroidal Melanomahttps://modernod.com/news/aura-biosciences-announces-positive-interim-phase-2-data-of-belzupacap-sarotalocan-for-treatment-of-early-stage-choroidal-melanoma/2481414/Aura Biosciences announced the presentation of positive interim phase 2 safety and efficacy data of belzupacap sarotalocan (bel-sar) with an average of 9 months of follow up evaluating two key clinical endpoints: tumor control, and visual acuity preservation using the suprachoroidal (SC) rou
- NIH: Gene Therapy for Rare Eye Disease Safe But Lacks Efficacy in Early Trialhttps://modernod.com/news/nih-gene-therapy-for-rare-eye-disease-safe-but-lacks-efficacy-in-early-trial/2480896/A 28-patient phase 1 gene therapy clinical trial for the degenerative retinal disease Leber hereditary optic neuropathy (LHON) found no significant safety concerns; however, treatment failed to improve or slow vision loss, with even the highest dose. LHON affects the optic nerve, which carries vi